by Paul | 19th December 2025 | News
London and New York, NY, December 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related... by admin | 29th August 2023 | News
New York and London, August 29, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the... by admin | 19th May 2023 | News
LONDON and NEW YORK, May 19, 2023 — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) hereby announces that following the implementation of the share capital consolidation and collapse of its ADS program, it is expected that new OKYO ordinary shares will be listed... by admin | 4th April 2023 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (“UK MAR”). NOTICE OF INTENTION TO DELIST...
